Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Rettenbacher

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
General Hospital Psychiatry|June 3, 2023
Does drug use affect the efficacy of amisulpride, aripiprazole and olanzapine in patients with schizophrenia spectrum disorders? Results from a pragmatic, randomised studyRenata Alisauskiene, Erik Johnsen, Rolf Gjestad, et al.
The International Journal of Neuropsychopharmacology|April 25, 2026
Three-week effect of amisulpride, aripiprazole, and olanzapine on gene expression in peripheral blood in individuals with schizophrenia spectrum disordersAnja Torsvik, Andrea Trentani, Tomasz K Stokowy, et al.
Brain, Behavior, & Immunity - Health|December 8, 2021
The association between cytokines and psychomotor speed in a spectrum of psychotic disorders: A longitudinal studyJeanette Brun Larsen, Solveig Klæbo Reitan, Else-Marie Løberg, et al.
NPJ Schizophrenia|August 19, 2021
Sex differences in antipsychotic efficacy and side effects in schizophrenia spectrum disorder: results from the BeSt InTro studySanne Hoekstra, Christoffer Bartz-Johannessen, Igne Sinkeviciute, et al.
Schizophrenia Research|January 12, 2023
Depression trajectories and cytokines in schizophrenia spectrum disorders - A longitudinal observational studyGunnhild E Hoprekstad, Eirik Kjelby, Rolf Gjestad, et al.
Psychiatry Research|January 24, 2018
Childhood trauma in schizophrenia spectrum disorders as compared to substance abuse disordersNina Mørkved, Dagfinn Winje, Anders Dovran, et al.
BMC Psychiatry|August 7, 2025
The relationship between childhood maltreatment and trauma and psychosis is not moderated by parental mental healthNina Mørkved, Pia Sophie Bryntesen, Ida Marie Eggen, et al.
Schizophrenia Research|April 4, 2024
Cellular adhesion molecules in drug-naïve and previously medicated patients with schizophrenia-spectrum disordersKristian Varden Gjerde, Christoffer Bartz-Johannessen, Vidar Martin Steen, et al.
Schizophrenia Research|February 4, 2026
Neural and vascular cellular adhesion molecules are associated with cognitive function in patients with schizophrenia-spectrum disorders: A longitudinal studyKristian Varden Gjerde, Christoffer Bartz-Johannessen, Else-Marie Løberg, et al.
Journal of Clinical Psychopharmacology|April 21, 2023
Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders: A Secondary Outcome Analysis of a Pragmatic, Randomized Trial (BeSt InTro)Eirik Kjelby, Rolf Gjestad, Farivar Fathian, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
General Hospital Psychiatry|June 3, 2023
Does drug use affect the efficacy of amisulpride, aripiprazole and olanzapine in patients with schizophrenia spectrum disorders? Results from a pragmatic, randomised studyRenata Alisauskiene, Erik Johnsen, Rolf Gjestad, et al.
The International Journal of Neuropsychopharmacology|April 25, 2026
Three-week effect of amisulpride, aripiprazole, and olanzapine on gene expression in peripheral blood in individuals with schizophrenia spectrum disordersAnja Torsvik, Andrea Trentani, Tomasz K Stokowy, et al.
Brain, Behavior, & Immunity - Health|December 8, 2021
The association between cytokines and psychomotor speed in a spectrum of psychotic disorders: A longitudinal studyJeanette Brun Larsen, Solveig Klæbo Reitan, Else-Marie Løberg, et al.
NPJ Schizophrenia|August 19, 2021
Sex differences in antipsychotic efficacy and side effects in schizophrenia spectrum disorder: results from the BeSt InTro studySanne Hoekstra, Christoffer Bartz-Johannessen, Igne Sinkeviciute, et al.
Schizophrenia Research|January 12, 2023
Depression trajectories and cytokines in schizophrenia spectrum disorders - A longitudinal observational studyGunnhild E Hoprekstad, Eirik Kjelby, Rolf Gjestad, et al.
Psychiatry Research|January 24, 2018
Childhood trauma in schizophrenia spectrum disorders as compared to substance abuse disordersNina Mørkved, Dagfinn Winje, Anders Dovran, et al.
BMC Psychiatry|August 7, 2025
The relationship between childhood maltreatment and trauma and psychosis is not moderated by parental mental healthNina Mørkved, Pia Sophie Bryntesen, Ida Marie Eggen, et al.
Schizophrenia Research|April 4, 2024
Cellular adhesion molecules in drug-naïve and previously medicated patients with schizophrenia-spectrum disordersKristian Varden Gjerde, Christoffer Bartz-Johannessen, Vidar Martin Steen, et al.
Schizophrenia Research|February 4, 2026
Neural and vascular cellular adhesion molecules are associated with cognitive function in patients with schizophrenia-spectrum disorders: A longitudinal studyKristian Varden Gjerde, Christoffer Bartz-Johannessen, Else-Marie Løberg, et al.
Journal of Clinical Psychopharmacology|April 21, 2023
Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders: A Secondary Outcome Analysis of a Pragmatic, Randomized Trial (BeSt InTro)Eirik Kjelby, Rolf Gjestad, Farivar Fathian, et al.
Pageof 3